Document is current

Any future updates will be listed below

Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases

Crossref DOI link: https://doi.org/10.1007/s00535-024-02141-8

Published Online: 2024-08-17

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark